Home / Stocks / RMD

ResMed (RMD, Health Care Equipment) Stock Valuation & Fair Value Trading above fair value

ResMed (RMD, Health Care Equipment) trades at a blended P/E of 20.2, about 25% below its historical normal valuation, with a forward growth estimate of 8.9% and a PEG of 2.27. Analysts' one-year estimates have been hit 73% of the time.

DATA AS OF 2026-08-21
Blended P/E
20.2
Normal P/E
27.0
PEG
2.27
Fwd growth
8.9%
Div yield
1.2%
RSI (14)
56.0
Neutral

The Street vs SeerForecast

Wall Street's mean price target for RMD is $247.20 across 15 analysts, 6.8% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: trading above fair value. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating moved from fairly valued (2026-06-03) to trading above fair value (2026-08-21).

Price and rating by weekClose moved +20.4 percent from 2026-06-03 to 2026-08-17, with 2 rating changes over 21 recorded weeks.2026-06-03: Fairly valued, close 186.46 (recalculated)2026-06-10: Fairly valued, close 193.57 (recalculated)2026-06-14: Fairly valued, close 194.78 (recalculated)2026-06-16: Fairly valued, close 193.94 (recalculated)2026-06-21: Fairly valued, close 188.63 (recalculated)2026-07-02: Fairly valued, close 209.63 (recalculated)2026-07-06: Fairly valued, close 218.40 (recalculated)2026-07-09: Fairly valued, close 208.45 (recalculated)2026-07-12: Fairly valued, close 203.87 (recalculated)2026-07-13: Fairly valued, close 198.50 (recalculated)2026-07-14: Fairly valued, close 193.01 (recalculated)2026-07-20: Fairly valued, close 198.61 (recalculated)2026-07-22: Fairly valued, close 192.91 (recalculated)2026-07-25: Fairly valued, close 195.27 (recalculated)2026-07-27: Fairly valued, close 203.08 (recalculated)2026-07-31: Fairly valued, close 210.98 (recalculated)2026-08-03: Fairly valued, close 210.982026-08-07: Trading above fair value, close 211.94 (recalculated)2026-08-10: Fairly valued, close 211.942026-08-14: Fairly valued, close 224.46 (recalculated)2026-08-17: Fairly valued, close 224.461862242026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 18.5-33%Fairly valued
2026-06-10P/E 17.8-36%Fairly valued
2026-06-14P/E 17.8-36%Fairly valued
2026-06-16P/E 17.8-36%Fairly valued
2026-06-21P/E 17.8-36%Fairly valued
2026-07-02P/E 18.1-35%Fairly valued
2026-07-06P/E 18.8-32%Fairly valued
2026-07-09P/E 18.8-32%Fairly valued
2026-07-12P/E 18.3-34%Fairly valued
2026-07-13P/E 18.3-34%Fairly valued
2026-07-14P/E 18.3-34%Fairly valued
2026-07-20P/E 17.8-36%Fairly valued
2026-07-22P/E 17.8-36%Fairly valued
2026-07-25P/E 17.5-37%Fairly valued
2026-07-27P/E 17.5-37%Fairly valued
2026-07-31P/E 18.6-33%Fairly valued
2026-08-03P/E 18.8-32%Fairly valued
2026-08-07P/E 19.8-27%Trading above fair value
2026-08-10P/E 18.8-30%Fairly valued
2026-08-14P/E 20.1-26%Fairly valued
2026-08-17P/E 19.9-26%Fairly valued
2026-08-21P/E 20.2-25%Trading above fair value ← now

Frequently asked questions

Is ResMed stock overvalued?

At a blended P/E of 20.2 versus its historical normal P/E of 27.0, ResMed trades about 25% below its typical valuation, with a PEG of 2.27 on 8.9% forward growth. tickerseer currently rates it trading above fair value.

What is ResMed's fair value and PEG?

ResMed trades at a blended P/E of 20.2 against a historical normal P/E of 27.0, a PEG of 2.27, and a forward growth estimate of 8.9%.

Has tickerseer's rating of ResMed changed?

tickerseer's rating moved from fairly valued (2026-06-03) to trading above fair value (2026-08-21).

What is the analyst price target for ResMed?

The mean Wall Street price target for ResMed is $247.20 across 15 analysts, 6.8% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Equipment. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track RMD free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.